[HTML][HTML] LRP1B: a giant lost in cancer translation
C Príncipe, IJ Dionísio de Sousa, H Prazeres… - Pharmaceuticals, 2021 - mdpi.com
Low-density lipoprotein receptor-related protein 1B (LRP1B) is a giant member of the LDLR
protein family, which includes several structurally homologous cell surface receptors with a …
protein family, which includes several structurally homologous cell surface receptors with a …
Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric …
A Stein, L Paschold, J Tintelnot, E Goekkurt… - JAMA …, 2022 - jamanetwork.com
Importance In metastatic esophagogastric adenocarcinoma (EGA), the addition of
programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in …
programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in …
[HTML][HTML] Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Tumour suppressor genes play a cardinal role in the development of a large array of human
cancers, including lung cancer, which is one of the most frequently diagnosed cancers …
cancers, including lung cancer, which is one of the most frequently diagnosed cancers …
[HTML][HTML] LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance
Accumulating evidence supports the association of somatic mutations with tumor occurrence
and development. We aimed to identify somatic mutations with important implications in …
and development. We aimed to identify somatic mutations with important implications in …
[HTML][HTML] A whole-slide foundation model for digital pathology from real-world data
Digital pathology poses unique computational challenges, as a standard gigapixel slide may
comprise tens of thousands of image tiles,–. Prior models have often resorted to …
comprise tens of thousands of image tiles,–. Prior models have often resorted to …
[HTML][HTML] Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest …
R Thomas, CA Wiley, EL Droste, J Robertson… - PLoS …, 2023 - journals.plos.org
Molecular profiling studies have shown that 85% of canine urothelial carcinomas (UC)
harbor an activating BRAF V595E mutation, which is orthologous to the V600E variant found …
harbor an activating BRAF V595E mutation, which is orthologous to the V600E variant found …
[HTML][HTML] Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcoma
Angiosarcomas are rare malignant tumors of the endothelium, arising commonly from the
head and neck region (AS-HN) and recently associated with ultraviolet (UV) exposure and …
head and neck region (AS-HN) and recently associated with ultraviolet (UV) exposure and …
Sequencing‐based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy
J Karolová, D Kazantsev, M Svatoň… - American journal of …, 2023 - Wiley Online Library
Our knowledge of genetic aberrations, that is, variants and copy number variations (CNVs),
associated with mantle cell lymphoma (MCL) relapse remains limited. A cohort of 25 patients …
associated with mantle cell lymphoma (MCL) relapse remains limited. A cohort of 25 patients …
DNA mutational profiling in patients with colorectal cancer treated with standard of care reveals differences in outcome and racial distribution of mutations
PURPOSE CALGB (Alliance)/SWOG 80405 was a randomized phase III trial that in first-line
patients with metastatic colorectal cancer (mCRC) treated with bevacizumab or cetuximab …
patients with metastatic colorectal cancer (mCRC) treated with bevacizumab or cetuximab …
[HTML][HTML] MDM2/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and …
TE Arnoff, WS El-Deiry - American Journal of Cancer Research, 2022 - ncbi.nlm.nih.gov
Metastatic melanoma has a five-year survival of~ 10%, with a paucity of biomarkers
predicting metastasis to specific anatomic sites or targeted therapies for metastases. We …
predicting metastasis to specific anatomic sites or targeted therapies for metastases. We …